Figure 2. Prevalence of G6PD Deficiency in US Veteran Population That Tested Positive for SARS-CoV-2 Infection.

Of the total male veterans (n = 3868) in this SARS-CoV-2–positive cohort (n = 4811), 10.8% (n = 418) had G6PD deficiency with the following distribution across racial ancestries: Black male veterans: 19.9% (309 of 1553), White male veterans: 3.7% (68 of 1855), and other male veterans (self-identified as neither Black nor White or self-identified as Asian, Pacific Islander, or American Indian or Alaska Native): 8.9% (41 of 460). Of the total female veterans of all racial ancestries (n = 907) in this SARS-CoV-2 positive cohort, 3.8% (36) had G6PD deficiency. These data show that the prevalence of G6PD deficiency in veterans positive for SARS-CoV-2 was higher than expected in the military population. All SARS-CoV-2 testing performed between February 15, 2020, to January 1, 2021. The percentages of US veterans with G6PD deficiency are presented as reported by the US Department of Defense.¹⁸